INNATE PHARMA (EPA:IPH) Innate Pharma SA has released the total number of shares outstanding and voting rights, as of March 31, 2010.

Transparency directive : regulatory news

08/04/2010 17:40

PRESS RELEASE

   NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT MARCH 31, 2010

Marseilles, April 8, 2010

Pursuant to the article L. 233-8 II of the French " Code de Commerce " and the
article 223-16 of the French stock-market authorities (Autorité des Marchés
Financiers, or "AMF") charter, Innate Pharma SA (the "Company" - Euronext Paris:
FR0010331421 - IPH) releases its total number of shares outstanding as well as
its voting rights as at March 31, 2010:

Total number of shares outstanding:      37,679,934
Voting rights:                           37,679,934

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at
December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code    FR0010331421
Ticker code  IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                  Alize Public Relations
Laure-Hélène Mercier           Caroline Carmagnol
Director, Investor Relations   Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87    Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com    caroline@alizerp.com

100406 IPH number of shares as of march 31 2010.DOCMarch 31, 2010

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA has released the total number of shares outstanding and voting rights, as of March 31, 2010.

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories